AC Immune

Update in progress

ACIU (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

AC Immune SA is a clinical‑stage biopharmaceutical company focused on neurodegenerative diseases linked to protein misfolding. Using SupraAntigen and Morphomer platforms, it develops biologics and small molecules that selectively target misfolded proteins. Its programs include Crenezumab and Semorinemab for Alzheimer's, ACI‑24.060 for Down syndrome–AD, and ACI‑7104.056 for Parkinson's, plus Tau imaging and diagnostic tools. It collaborates with Genentech, Janssen, Life Molecular Imaging and Eli Lilly and is based in Lausanne, Switzerland.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.05; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGM (NGM)
LocationSwitzerland
CEODr. Martin Zugel M.D., Ph.D.
Founded2003
Employees90
Websitewww.acimmune.com

Identifiers

ISINCH0329023102
FIGIBBG00D0RHJ38
LEI967600VLQ0ZC2HSOG765
CUSIPH00263105
CIK0001651625